Home › Companies › CMPX

Compass Therapeutics

CMPX Lead: Phase 2 ★ Read the deep dive → 1 Biotech Distilled article ↓

Oncology Protein

Most recent annual filing: 2026-03-05

Pipeline (9 active programs)

tovecimig

CTX-009

Protein Target: DLL4, VEGF-A

Biliary Tract Cancer Phase 2 Phase 2/3 trial ABL Bio

tovecimib

CTX-009

Protein Target: DLL4, VEGF-A

Colorectal Cancer Phase 2 ABL Bio

Undisclosed indication Phase 1

Technology platforms

StitchMabs

Bispecific antibody discovery platform using combinatorial screening of antigen-binding domain pairs across innate and adaptive immune targets; used to identify novel bispecific antibodies for oncology applications

Biotech Distilled coverage (1)

2026-08-25 Compass Therapeutics (CMPX) — Scientific Deep Dive for Tovecimig and the Bispecific Antibody Pipeline

Articles open on Substack. Some deep dives are subscriber-only.

Pipeline (9 active programs)

tovecimig

tovecimib

CTX-471

CTX-8371

CTX-10726

Technology platforms

StitchMabs

Biotech Distilled coverage (1)